Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|February 15, 2023

BP Elements

  • BioPharm International's BP Elements, March 2023
  • Volume 2
  • Issue 3

Charles River Launches Novel IgY-based ELISA Kit

The kit is meant for use for the detection and quantitation of residual host cell protein.

Charles River Laboratories announced on Feb. 13, 2023 the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) kit for the detection and quantitation of residual host cell proteins (HCP) in Chinese hamster ovary (CHO)-based biotherapeutics.

The new HCP-ELISA kit leverages avian immunoglobulin Y (IgY) antibodies as the primary detection technology. These antibodies are derived from specific-pathogen-free chicken (SPF) eggs developed exclusively by AVS Bio. The HCP-ELISA kit builds upon Charles River’s HCP-GAPex service, increasing the efficiency and efficacy of HCP assay development.

“With more than 30 years of impurity testing experience, host cell protein assays are one of our core competencies,” said Kerstin Dolph, corporate senior vice president, biologics solutions, Charles River, in a company press release. “Building on that expertise to bring our inaugural kit to market was the next logical step to strengthen our Biologics Testing offering.”

Source: Charles River

Articles in this issue

over 3 years ago

Evolutions in Vaccine Development

over 3 years ago

Advances in In Vivo CAR T-cell Therapies

over 3 years ago

FDA Issues Guidance on Potency for mAbs and Therapeutic Proteins

over 3 years ago

Bio-Rad’s New StarBright Blue and Yellow Dyes Enhance Multiplex Flow Cytometry

over 3 years ago

Eurofins Viracor Launches Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients

over 3 years ago

Moderna and Life Edit Therapeutics Enter Gene Editing Collaboration

over 3 years ago

AbbVie and Capsida Strike $674 Million Gene Therapy Development Deal

over 3 years ago

Predictive Oncology and Cvergenx Enter Genomics-Based Personalized Therapy Collaboration

almost 4 years ago

iotaSciences Launches Single-Cell Picker

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more